Drugs that contain Treprostinil

1. List of Remodulin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil
Dec, 2024

(1 year, 10 months from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil
Dec, 2024

(1 year, 10 months from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil
Dec, 2024

(1 year, 10 months from now)

US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(5 years from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(5 years from now)

US7999007 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Mar, 2029

(6 years from now)

Market Authorisation Date: 21 May, 2002

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

How can I launch a generic of REMODULIN before it's patent expiration?
More Information on Dosage

REMODULIN family patents

50

United States

10

China

10

Japan

7

Canada

7

European Union

6

Korea, Republic of

6

Spain

1

Austria

1

Germany

2. List of Tyvaso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US10376525 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation
Mar, 2028

(5 years from now)

US9358240 UNITED THERAP Treprostinil administration by inhalation
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 31, 2024

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION;INHALATION

How can I launch a generic of TYVASO before it's patent expiration?
More Information on Dosage

TYVASO family patents

23

United States

6

Japan

4

Korea, Republic of

3

China

3

European Union

2

Spain

2

Canada

3. List of Tyvaso Dpi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130685 UNITED THERAP Diketopiperazine salts for drug delivery and related methods
Aug, 2025

(2 years from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US10772883 UNITED THERAP Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(7 years from now)

US10421729 UNITED THERAP Microcrystalline diketopiperazine compositions and methods
Apr, 2035

(12 years from now)

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: POWDER;INHALATION

More Information on Dosage

TYVASO DPI family patents

50

United States

18

Korea, Republic of

13

Japan

9

China

9

European Union

7

Australia

7

Spain

5

Canada

4

Hong Kong

4

Brazil

4

Israel

4

Mexico

3

Poland

3

Hungary

3

Singapore

3

Denmark

2

Malaysia

1

Argentina

1

Russia

1

Taiwan, Province of China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic